Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China - February 15, 2019

Pharmacy News Article

 2/10/19 - Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
  • Agreement covers Samsung Bioepis third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS 1 (ranibizumab) and SOLIRIS 2 (eculizumab), respectively
  • Partnership brings together Samsung Bioepis proven agile biologics development platform and C-Bridge's strong capital resource and China healthcare expertise
  • C-Bridge Capital forms new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis next-generation biosimilars in China.

INCHEON, Korea(BUSINESS WIRE) Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing HERCEPTIN 3 (trastuzumab).

Under the agreement, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration and commercialization in China. Samsung Bioepis will receive an upfront payment, as well as royalties on sales. Additional financial details were not disclosed.

We want to play an important role in widening access to high-quality healthcare for patients throughout China. C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond, said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.

Established in February 2012, Samsung Bioepis currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI? (etanercept), FLIXABI? (infliximab) and IMRALDI? (adalimumab), as well as an oncologic biosimilar, ONTRUZANT (trastuzumab). In the United States, the company has one biosimilar RENFLEXIS (infliximab-abda) .on the market, while another biosimilar ONTRUZANT (trastuzumab-dttb) has been approved by the U.S. Food and Drug Administration (FDA). A Biologics License Application (BLA) for SB5 (adalimumab) biosimilar candidate is currently under review at the FDA.

In total, over 100,000 patients across the world are currently under treatment with Samsung Bioepis biosimilars, with over 6 million doses administered.

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities across healthcare industry. C-Bridge Capital's current portfolio includes China's leading players in pharmaceuticals, medical devices, diagnosis and healthcare services. As of today, the AUM of C-Bridge Capital has exceeded US$1.8 Billion. C-Bridge Capital is committed to support commercialization of cutting-edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

1 LUCENTIS is a registered trademark of Genentech

2 SOLIRIS is a registered trademark of Alexion

3 HERCEPTIN is a registered trademark of Genentech

MEDIA:

Mingi Hyun

+82-31-8061-1594

mingi.hyun@samsung.com

Source: Samsung Bioepis Co., Ltd.



Copyright Business Wire 2019

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415